William Ho, a newly appointed director at Spero Therapeutics, Inc., filed an initial statement of beneficial ownership on November 10, 2026, disclosing no securities held in the company.

Key Highlights

  • Reporting person: William Ho, identified as a Director of Spero Therapeutics, Inc. (NASDAQ:SPRO).
  • Date of event: The filing is dated November 10, 2026, which is also the stated date of the event requiring the statement.
  • No securities held: The filing states, "No securities are beneficially owned," with both Table I (non-derivative securities) and Table II (derivative securities) left blank.
  • Signed by attorney-in-fact: The form was signed by Maegan Deare as attorney-in-fact for William Ho on November 10, 2026.
  • Power of attorney noted: The filing references a Director Exhibit 24.1 as a Power of Attorney.

William Ho's Initial Ownership Disclosure at Spero Therapeutics

William Ho filed a Form 3, Initial Statement of Beneficial Ownership of Securities, with the U.S. Securities and Exchange Commission on November 10, 2026, in connection with his role as a Director at Spero Therapeutics, Inc., listed on NASDAQ under the symbol SPRO. The filing was submitted pursuant to Section 16(a) of the Securities Exchange Act of 1934, which requires officers, directors, and certain shareholders to report their initial beneficial ownership of a company's securities upon assuming a reporting relationship.

According to the filing, Ho holds no securities in Spero Therapeutics at the time of this initial statement. Table I, covering non-derivative securities such as common stock, contains no entries. Table II, covering derivative securities such as options, warrants, or convertible instruments, is likewise blank. The filing explicitly states, "No securities are beneficially owned."

The form was signed by Maegan Deare as attorney-in-fact for William Ho, with the signing date recorded as November 10, 2026. The filing references Director Exhibit 24.1, described as a Power of Attorney. Ho's address is listed as c/o 675 Massachusetts Avenue, 14th Floor, Cambridge, Massachusetts 02139.

What Was Disclosed

William Ho, a Director of Spero Therapeutics, Inc., filed an initial beneficial ownership statement reporting no holdings of any direct or indirect securities, derivative or non-derivative, as of November 10, 2026.